SpyGlass Pharma acquires Advanced Vision Science for $13m to secure intraocular lens manufacturing
SpyGlass Pharma has acquired Advanced Vision Science for approximately $13 million, bringing manufacturing of a key intraocular lens used in its drug-delivery platform in-house.
The acquired business manufactures the intraocular lens used in SpyGlass' Phase III BIM-IOL System, which is being developed as a sustained ophthalmic drug-delivery platform.
The acquisition gives SpyGlass direct control over an important manufacturing capability as it prepares for potential commercialisation and future expansion of the platform.
Field | Content |
Article Type | Deals |
Companies | SpyGlass Pharma; Advanced Vision Science; Santen |
Deal Type | Acquisition |
Transaction Value | Approximately $13 million in cash |
Acquired Company | Advanced Vision Science |
Therapy Area | Ophthalmology |
Technology/Modality | Intraocular lens manufacturing and sustained ophthalmic drug delivery |
Key Programme | BIM-IOL System |
Development Stage | Phase III |
What Happened | SpyGlass Pharma acquired 100% of Advanced Vision Science from Santen for approximately $13 million in cash. |
Why It Matters | Advanced Vision Science manufactures the intraocular lens used in SpyGlass' Phase III BIM-IOL System, making the acquisition strategically important to future supply and commercialisation. |
Strategic Rationale | Owning the manufacturing capability gives SpyGlass greater control over production, scale-up and potential commercial supply. |
Potential Impact | The transaction could reduce supply-chain dependence and support expansion of SpyGlass' ophthalmic drug-delivery platform. |
Key Takeaway | SpyGlass has acquired a critical intraocular-lens manufacturing business supporting its Phase III ophthalmology platform. |
What to Watch | Integration of AVS, Phase III progress for BIM-IOL and commercial manufacturing scale-up. |
Primary Source | SpyGlass Pharma |
Relevant Date | 1 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글